![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The net proceeds will be used to support the continued clinical development of QLS‑111, a first-in-class therapeutic being developed to lower intraocular pressure by targeting episcleral venous pressure in patients with open angle glaucoma and ocular hypertension.
Lead Product(s): QLS-111
Therapeutic Area: Ophthalmology Product Name: QLS-111
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Canaan
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 30, 2024
Details:
Study findings demonstrated a favorable safety and tolerability profile for QLS-101, including no evidence of hyperemia (eye redness), as well as a positive efficacy signal, in patients with primary open-angle glaucoma (POAG) or ocular hypertension.
Lead Product(s): QLS-101
Therapeutic Area: Ophthalmology Product Name: QLS-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
QLS-101 is a novel adenosine triphosphate (ATP)-sensitive potassium (KATP) channel modulator administered as a topical eyedrop. QLS-101 specifically lowers EVP, a key determinant of IOP, or fluid pressure in the eye, which can be elevated in individuals with glaucoma.
Lead Product(s): QLS-101,Timolol Maleate
Therapeutic Area: Ophthalmology Product Name: QLS-101
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021